Key Details
Annual Revenue
$10.83 MAnnual ROE
140.89%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 10, 2022Recent annual earnings:
Mar 24, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
24 Oct '22 Cowen & Co.
Market Perform28 Sept '22 William Blair
Market Perform28 Sept '22 Needham
Hold15 Aug '22 Needham
Buy28 Mar '22 Needham
Buy17 June '21 Needham
Buy16 Mar '21 Needham
Buy06 Apr '20 Citigroup
Buy03 Oct '19 HC Wainwright & Co.
Buy09 Sept '19 Stifel
BuyScreeners with PHAS included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
PhaseBio Pharmaceuticals doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of PhaseBio Pharmaceuticals?
- What is the ticker symbol for PhaseBio Pharmaceuticals?
- Does PhaseBio Pharmaceuticals pay dividends?
- What sector is PhaseBio Pharmaceuticals in?
- What industry is PhaseBio Pharmaceuticals in?
- What country is PhaseBio Pharmaceuticals based in?
- When did PhaseBio Pharmaceuticals go public?
- Is PhaseBio Pharmaceuticals in the S&P 500?
- Is PhaseBio Pharmaceuticals in the NASDAQ 100?
- Is PhaseBio Pharmaceuticals in the Dow Jones?
- When was PhaseBio Pharmaceuticals's last earnings report?
- When does PhaseBio Pharmaceuticals report earnings?
What is the primary business of PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.
What is the ticker symbol for PhaseBio Pharmaceuticals?
The ticker symbol for PhaseBio Pharmaceuticals is NASDAQ:PHAS
Does PhaseBio Pharmaceuticals pay dividends?
No, PhaseBio Pharmaceuticals does not pay dividends
What sector is PhaseBio Pharmaceuticals in?
PhaseBio Pharmaceuticals is in the Healthcare sector
What industry is PhaseBio Pharmaceuticals in?
PhaseBio Pharmaceuticals is in the Biotechnology industry
What country is PhaseBio Pharmaceuticals based in?
PhaseBio Pharmaceuticals is headquartered in United States
When did PhaseBio Pharmaceuticals go public?
PhaseBio Pharmaceuticals's initial public offering (IPO) was on 18 October 2018
Is PhaseBio Pharmaceuticals in the S&P 500?
No, PhaseBio Pharmaceuticals is not included in the S&P 500 index
Is PhaseBio Pharmaceuticals in the NASDAQ 100?
No, PhaseBio Pharmaceuticals is not included in the NASDAQ 100 index
Is PhaseBio Pharmaceuticals in the Dow Jones?
No, PhaseBio Pharmaceuticals is not included in the Dow Jones index
When was PhaseBio Pharmaceuticals's last earnings report?
PhaseBio Pharmaceuticals's most recent earnings report was on 10 November 2022
When does PhaseBio Pharmaceuticals report earnings?
The date for PhaseBio Pharmaceuticals's next earnings report has not been announced yet